NCT03758989View on ClinicalTrials.gov

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 8, 2019

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2027

Conditions
DLBCL
Interventions
DRUG

Rituximab Prednisone

A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

DRUG

Cyclophosphamide

A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

DRUG

Doxorubicin

A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

DRUG

Vincristine

A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

DRUG

Prednisone

A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

Trial Locations (1)

14642

RECRUITING

University of Rochester, Rochester

All Listed Sponsors
lead

University of Rochester

OTHER